{"parse":{"title":"Ethics in pharmaceutical sales","pageid":13789612,"revid":858207187,"text":{"*":"<div class=\"mw-parser-output\"><p>The <b>ethics involved within pharmaceutical sales</b> is built from the <a href=\"/wiki/Organizational_ethics\" title=\"Organizational ethics\">organizational ethics</a>, which is a matter of system compliance, accountability and culture (Grace &amp; Cohen, 2005). Organizational ethics are used when developing the marketing and sales strategy to both the public and the healthcare profession of the strategy.<sup id=\"cite_ref-NYT-20151127_1-0\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup> Organizational ethics are best demonstrated through acts of fairness, compassion, integrity, honor, and responsibility.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Industry\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Industry</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Sales_practices\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Sales practices</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Regulations_and_guidelines\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Regulations and guidelines</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#European_Federation_of_Pharmaceutical_Industries_and_Associations\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">European Federation of Pharmaceutical Industries and Associations</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Pharmaceutical_Research_and_Manufacturers_of_America\"><span class=\"tocnumber\">3.2</span> <span class=\"toctext\">Pharmaceutical Research and Manufacturers of America</span></a></li>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#U.S._Department_of_Health_and_Human_Services\"><span class=\"tocnumber\">3.3</span> <span class=\"toctext\">U.S. Department of Health and Human Services</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#Health_care_fraud\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Health care fraud</span></a></li>\n<li class=\"toclevel-1 tocsection-8\"><a href=\"#Advocacy_groups\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Advocacy groups</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#No_Free_Lunch\"><span class=\"tocnumber\">5.1</span> <span class=\"toctext\">No Free Lunch</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#See_also\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#References\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-12\"><a href=\"#Further_reading\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">Further reading</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Industry\">Industry</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=1\" title=\"Edit section: Industry\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The pharmaceutical industry is a highly competitive business and its success is dependent on the sales and marketing of each drug.<sup id=\"cite_ref-NYT-20151127_1-1\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup> The cost of research and development for each drug is hundreds of millions of dollars. In 2005 the research and development expenditure for the biopharmaceutical industry within Europe and the US was 15,474 million euro.(The Pharma Industry Figures, 2006). Some health economists peg the current cost of drug development at US$1.3 billion, others at US$1.7 billion<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> The actual <a href=\"/wiki/Drug_discovery\" title=\"Drug discovery\">drug discovery</a> and the <a href=\"/wiki/Drug_development\" title=\"Drug development\">drug development</a> can take years. After which, testing and clinical trials are required prior to getting approval by regulatory boards. After launching the drug the company has much at stake as it has already outlaid millions of dollars the success of its sales is an important factor to the success of the company.\n</p>\n<h2><span class=\"mw-headline\" id=\"Sales_practices\">Sales practices</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=2\" title=\"Edit section: Sales practices\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>A pharmaceutical sales representative is the key part within the sales of all drugs.<sup id=\"cite_ref-NYT-20151127_1-2\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup> They are responsible to ensure the healthcare profession is informed of the benefits of the drug along with the safety and the side effects to assist a healthcare profession as the correct information and choices to prescribe medication to the patients. The term used is ethical promotion, which can be described as communication of ethical values to promote their product to the physician. (Wright &amp; Lundstrom, 2004)\n</p>\n<h2><span class=\"mw-headline\" id=\"Regulations_and_guidelines\">Regulations and guidelines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=3\" title=\"Edit section: Regulations and guidelines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"European_Federation_of_Pharmaceutical_Industries_and_Associations\">European Federation of Pharmaceutical Industries and Associations</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=4\" title=\"Edit section: European Federation of Pharmaceutical Industries and Associations\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The <a href=\"/wiki/European_Federation_of_Pharmaceutical_Industries_and_Associations\" title=\"European Federation of Pharmaceutical Industries and Associations\">European Federation of Pharmaceutical Industries and Associations</a> (EFPIA) stipulates that there is a Corporate Social responsibility for the pharmaceutical industry to recognize and acknowledge the need to act responsibly towards society and the communities in which it operates.\n</p><p>The EFPIA has also code of practice on the promotion of medicine, which entails the regulations over many areas of the promotion of medicine. These include events and hospitality that can be extended by a pharmaceutical company. Gifts and inducements must be inexpensive and provide value to the practice of medicine or pharmacy. All medical sales representatives must have the adequate training and sufficient scientific knowledge to provide relevant and precise information about the products. They must also comply with the requirements of the applicable codes.\n</p>\n<h3><span class=\"mw-headline\" id=\"Pharmaceutical_Research_and_Manufacturers_of_America\">Pharmaceutical Research and Manufacturers of America</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=5\" title=\"Edit section: Pharmaceutical Research and Manufacturers of America\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/Pharmaceutical_Research_and_Manufacturers_of_America\" title=\"Pharmaceutical Research and Manufacturers of America\">Pharmaceutical Research and Manufacturers of America</a></div>\n<p>In 2002 the <a href=\"/wiki/Pharmaceutical_Research_and_Manufacturers_of_America\" title=\"Pharmaceutical Research and Manufacturers of America\">Pharmaceutical Research and Manufacturers of America</a>, issued a set of guidelines for its member companies to follow when it comes to the relationship between drug reps and doctors. The voluntary code significantly changed how drug company representatives interact with doctors. Changes range from restricting gifts to limiting consulting contracts offered to doctors.<sup id=\"cite_ref-Baltimore_4-0\" class=\"reference\"><a href=\"#cite_note-Baltimore-4\">&#91;4&#93;</a></sup>\n</p><p>PhRMA was inspired to come up with the code after years of criticism from groups like <a href=\"/wiki/Families_USA\" title=\"Families USA\">Families USA</a> and <a href=\"/wiki/Public_Citizen\" title=\"Public Citizen\">Public Citizen</a>. PhRMA already had a set of guidelines on this topic but its board decided that one of the best ways to thwart the criticism and prevent any appearance of impropriety was to come up with a stricter code.<sup id=\"cite_ref-Baltimore_4-1\" class=\"reference\"><a href=\"#cite_note-Baltimore-4\">&#91;4&#93;</a></sup>\n</p><p>\"The PhRMA guidelines are one major factor contributing to a paradigm shift that directly impacts the way our industry conducts business,\"\"Because of this shift, pharmaceutical sales forces must learn new and more compelling ways to create and keep customers, or perish because physicians are no longer willing to listen to their usual approach,\"  said Susan Torroella, CEO of Columbia MedCom Group.<sup id=\"cite_ref-Baltimore_4-2\" class=\"reference\"><a href=\"#cite_note-Baltimore-4\">&#91;4&#93;</a></sup>\n</p><p>PhRMA is opposed to state laws that regulate interaction between <a href=\"/wiki/Pharmaceutical_sales_representative\" title=\"Pharmaceutical sales representative\">pharmaceutical sales representatives</a> and health care providers. PhRMA officials said state regulations could create a patchwork of conflicting rules across the states that might do more to confuse sales representatives and doctors than prevent improper perks.\"We do have the comprehensive guidelines combined with the guidelines of the Office of Inspector General. Not only would state laws be a duplication, it could be nightmarish because you would have differing standards for different states,\" said Jeff Trewhitt, a spokesman for PhRMA.<sup id=\"cite_ref-Baltimore_4-3\" class=\"reference\"><a href=\"#cite_note-Baltimore-4\">&#91;4&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"U.S._Department_of_Health_and_Human_Services\">U.S. Department of Health and Human Services</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=6\" title=\"Edit section: U.S. Department of Health and Human Services\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/United_States_Department_of_Health_and_Human_Services\" title=\"United States Department of Health and Human Services\">United States Department of Health and Human Services</a></div>\n<p>After PhRMA enacted its guidelines, the Office of Inspector General for the U.S. Department of Health and Human Services issued guidelines similar to PhRMA's code, except with more severe penalties. Companies that fail to follow the department's rules could face a federal investigation that could lead to civil penalties.<sup id=\"cite_ref-Baltimore_4-4\" class=\"reference\"><a href=\"#cite_note-Baltimore-4\">&#91;4&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Health_care_fraud\">Health care fraud</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=7\" title=\"Edit section: Health care fraud\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">See also: <a href=\"/wiki/List_of_largest_pharmaceutical_settlements_in_the_United_States\" class=\"mw-redirect\" title=\"List of largest pharmaceutical settlements in the United States\">List of largest pharmaceutical settlements in the United States</a> and <a href=\"/wiki/List_of_off-label_promotion_pharmaceutical_settlements\" title=\"List of off-label promotion pharmaceutical settlements\">List of off-label promotion pharmaceutical settlements</a></div>\n<p><a href=\"/wiki/Pharmaceutical_fraud\" title=\"Pharmaceutical fraud\">Pharmaceutical fraud</a> involves activities that result in false claims to insurers or programs such as <a href=\"/wiki/Medicare_(United_States)\" title=\"Medicare (United States)\">Medicare</a> in the United States or equivalent state programs for financial gain to a pharmaceutical company.<sup id=\"cite_ref-NYT-20151127_1-3\" class=\"reference\"><a href=\"#cite_note-NYT-20151127-1\">&#91;1&#93;</a></sup> There are several different schemes<sup id=\"cite_ref-FBIFraudTypes_5-0\" class=\"reference\"><a href=\"#cite_note-FBIFraudTypes-5\">&#91;5&#93;</a></sup> used to defraud the <a href=\"/wiki/Health_care_system\" class=\"mw-redirect\" title=\"Health care system\">health care system</a> which are particular to the pharmaceutical industry. These include: Good Manufacturing Practice (GMP) Violations, Off Label Marketing, Best Price Fraud, CME Fraud, Medicaid Price Reporting, and Manufactured Compound Drugs. The <a href=\"/wiki/Federal_Bureau_of_Investigation\" title=\"Federal Bureau of Investigation\">Federal Bureau of Investigation</a> (FBI) estimates that <a href=\"/wiki/Health_care_fraud\" title=\"Health care fraud\">health care fraud</a> costs American taxpayers $60 billion a year.<sup id=\"cite_ref-FBIHealthCareGeneral_6-0\" class=\"reference\"><a href=\"#cite_note-FBIHealthCareGeneral-6\">&#91;6&#93;</a></sup> Of this amount $2.5 billion was recovered through <i>False Claims Act</i> cases in FY 2010. Examples of fraud cases include the <a href=\"/wiki/Pfizer\" title=\"Pfizer\">Pfizer</a> $2.3 billion settlement and <a href=\"/wiki/Merck_%26_Co.\" title=\"Merck &amp; Co.\">Merck</a> $650 million settlement. Damages from fraud can be recovered by use of the <a href=\"/wiki/False_Claims_Act\" title=\"False Claims Act\">False Claims Act</a>, most commonly under the <i><a href=\"/wiki/Qui_tam\" title=\"Qui tam\">qui tam</a></i> provisions which rewards an individual for being a \"<a href=\"/wiki/Whistleblower\" title=\"Whistleblower\">whistleblower</a>\", or <a href=\"/wiki/Relator_(law)\" title=\"Relator (law)\">relator (law)</a>.<sup id=\"cite_ref-DOJHealthCareFraudReport_7-0\" class=\"reference\"><a href=\"#cite_note-DOJHealthCareFraudReport-7\">&#91;7&#93;</a></sup>\n</p><p>Antipsychotic drugs are now the top-selling class of pharmaceuticals in America, generating annual revenue of about $14.6 billion. Every major company selling the drugs \u2014 <a href=\"/wiki/Bristol-Myers_Squibb\" title=\"Bristol-Myers Squibb\">Bristol-Myers Squibb</a>, <a href=\"/wiki/Eli_Lilly\" title=\"Eli Lilly\">Eli Lilly</a>, <a href=\"/wiki/Pfizer\" title=\"Pfizer\">Pfizer</a>, <a href=\"/wiki/AstraZeneca\" title=\"AstraZeneca\">AstraZeneca</a> and <a href=\"/wiki/Johnson_%26_Johnson\" title=\"Johnson &amp; Johnson\">Johnson &amp; Johnson</a> \u2014 has either settled recent government cases, under the False Claims Act, for hundreds of millions of dollars or is currently under investigation for possible health care fraud. Following charges of illegal marketing, two of the settlements set records last year for the largest criminal fines ever imposed on corporations. One involved Eli Lilly\u2019s antipsychotic <a href=\"/wiki/Zyprexa\" class=\"mw-redirect\" title=\"Zyprexa\">Zyprexa</a>, and the other involved  <a href=\"/wiki/Bextra\" class=\"mw-redirect\" title=\"Bextra\">Bextra</a>. In the Bextra case, the government also charged Pfizer with illegally marketing another antipsychotic, <a href=\"/wiki/Geodon\" class=\"mw-redirect\" title=\"Geodon\">Geodon</a>; Pfizer settled that part of the claim for $301 million, without admitting any wrongdoing.<sup id=\"cite_ref-bied2010_8-0\" class=\"reference\"><a href=\"#cite_note-bied2010-8\">&#91;8&#93;</a></sup>\n</p><p>On 2 July 2012, <a href=\"/wiki/GlaxoSmithKline\" title=\"GlaxoSmithKline\">GlaxoSmithKline</a> pleaded guilty to criminal charges and agreed to a $3 billion settlement of the largest health-care fraud case in the U.S. and the largest payment by a drug company.<sup id=\"cite_ref-9\" class=\"reference\"><a href=\"#cite_note-9\">&#91;9&#93;</a></sup> The settlement is related to the company's illegal promotion of prescription drugs, its failure to report safety data,<sup id=\"cite_ref-10\" class=\"reference\"><a href=\"#cite_note-10\">&#91;10&#93;</a></sup> <a href=\"/wiki/Bribing\" class=\"mw-redirect\" title=\"Bribing\">bribing</a> doctors, and promoting medicines for uses for which they were not licensed. The drugs involved were <a href=\"/wiki/Paxil\" class=\"mw-redirect\" title=\"Paxil\">Paxil</a>, <a href=\"/wiki/Wellbutrin\" class=\"mw-redirect\" title=\"Wellbutrin\">Wellbutrin</a>, <a href=\"/wiki/Advair\" class=\"mw-redirect\" title=\"Advair\">Advair</a>, <a href=\"/wiki/Lamictal\" class=\"mw-redirect\" title=\"Lamictal\">Lamictal</a>, and <a href=\"/wiki/Zofran\" class=\"mw-redirect\" title=\"Zofran\">Zofran</a> for off-label, non-covered uses. Those and the drugs <a href=\"/wiki/Imitrex\" class=\"mw-redirect\" title=\"Imitrex\">Imitrex</a>, <a href=\"/wiki/Lotronex\" class=\"mw-redirect\" title=\"Lotronex\">Lotronex</a>, <a href=\"/wiki/Flovent\" class=\"mw-redirect\" title=\"Flovent\">Flovent</a>, and <a href=\"/wiki/Valtrex\" class=\"mw-redirect\" title=\"Valtrex\">Valtrex</a> were involved in the <a href=\"/wiki/Kickback_(bribery)\" title=\"Kickback (bribery)\">kickback scheme</a>.<sup id=\"cite_ref-11\" class=\"reference\"><a href=\"#cite_note-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup><sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup>\n</p><p>The following is a list of the four largest settlements reached with <a href=\"/wiki/Pharmaceutical_industry\" title=\"Pharmaceutical industry\">pharmaceutical companies</a> from 1991 to 2012, rank ordered by the size of the total settlement. Legal claims against the pharmaceutical industry have varied widely over the past two decades, including <a href=\"/wiki/Medicare_fraud\" title=\"Medicare fraud\">Medicare and Medicaid fraud</a>, <a href=\"/wiki/Off-label_use\" title=\"Off-label use\">off-label</a> promotion, and inadequate manufacturing practices.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup><sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup>\n</p>\n<table class=\"wikitable\">\n\n<tbody><tr>\n<th>Company</th>\n<th>Settlement</th>\n<th>Violation(s)</th>\n<th>Year</th>\n<th>Product(s)</th>\n<th>Laws allegedly violated <br /> (if applicable)\n</th></tr>\n<tr>\n<td><a href=\"/wiki/GlaxoSmithKline\" title=\"GlaxoSmithKline\">GlaxoSmithKline</a><sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup></td>\n<td>$3 billion</td>\n<td>Off-label promotion/ <br /> failure to disclose safety data</td>\n<td>2012</td>\n<td><a href=\"/wiki/Rosiglitazone\" title=\"Rosiglitazone\">Avandia</a>/<a href=\"/wiki/Bupropion\" title=\"Bupropion\">Wellbutrin</a>/<a href=\"/wiki/Paroxetine\" title=\"Paroxetine\">Paxil</a></td>\n<td><a href=\"/wiki/False_Claims_Act\" title=\"False Claims Act\">False Claims Act</a>/<a href=\"/wiki/Federal_Food,_Drug,_and_Cosmetic_Act\" title=\"Federal Food, Drug, and Cosmetic Act\">FDCA</a>\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Pfizer\" title=\"Pfizer\">Pfizer</a><sup id=\"cite_ref-17\" class=\"reference\"><a href=\"#cite_note-17\">&#91;17&#93;</a></sup></td>\n<td>$2.3 billion</td>\n<td>Off-label promotion/ <br /> <a href=\"/wiki/Kickbacks\" class=\"mw-redirect\" title=\"Kickbacks\">kickbacks</a></td>\n<td>2009</td>\n<td><a href=\"/wiki/Valdecoxib\" title=\"Valdecoxib\">Bextra</a>/<a href=\"/wiki/Ziprasidone\" title=\"Ziprasidone\">Geodon</a>/ <br /> <a href=\"/wiki/Linezolid\" title=\"Linezolid\">Zyvox</a>/<a href=\"/wiki/Pregabalin\" title=\"Pregabalin\">Lyrica</a></td>\n<td>False Claims Act/FDCA\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Abbott_Laboratories\" title=\"Abbott Laboratories\">Abbott Laboratories</a><sup id=\"cite_ref-18\" class=\"reference\"><a href=\"#cite_note-18\">&#91;18&#93;</a></sup></td>\n<td>$1.5 billion</td>\n<td>Off-label promotion</td>\n<td>2012</td>\n<td><a href=\"/wiki/Valproic_acid\" class=\"mw-redirect\" title=\"Valproic acid\">Depakote</a></td>\n<td>False Claims Act/FDCA\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Eli_Lilly_and_Company\" title=\"Eli Lilly and Company\">Eli Lilly</a><sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup></td>\n<td>$1.4 billion</td>\n<td>Off-label promotion</td>\n<td>2009</td>\n<td><a href=\"/wiki/Olanzapine\" title=\"Olanzapine\">Zyprexa</a></td>\n<td>False Claims Act/FDCA\n</td></tr></tbody></table>\n<h2><span class=\"mw-headline\" id=\"Advocacy_groups\">Advocacy groups</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=8\" title=\"Edit section: Advocacy groups\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"No_Free_Lunch\">No Free Lunch</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=9\" title=\"Edit section: No Free Lunch\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div role=\"note\" class=\"hatnote navigation-not-searchable\">Main article: <a href=\"/wiki/No_Free_Lunch_(organization)\" title=\"No Free Lunch (organization)\">No Free Lunch (organization)</a></div>\n<p>Some physicians have joined an organization No free lunch which asked physicians to make a pledge to not accept any pharmaceutical companies gifts no matter how large or small. The members base that gift giving forms relationships, which influences behaviour and creates a conflict of interest. (No Free Lunch)\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=10\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Inverse_benefit_law\" title=\"Inverse benefit law\">Inverse benefit law</a></li>\n<li><a href=\"/wiki/Pharmaceutical_marketing\" title=\"Pharmaceutical marketing\">Pharmaceutical marketing</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=11\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-NYT-20151127-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-NYT-20151127_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-NYT-20151127_1-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-NYT-20151127_1-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-NYT-20151127_1-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">The Editorial Board (November 27, 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2015/11/27/opinion/turn-the-volume-down-on-drug-ads.html\">\"Turn the Volume Down on Drug Ads\"</a>. <i><a href=\"/wiki/New_York_Times\" class=\"mw-redirect\" title=\"New York Times\">New York Times</a></i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">November 27,</span> 2015</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=Turn+the+Volume+Down+on+Drug+Ads&amp;rft.date=2015-11-27&amp;rft.au=The+Editorial+Board&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2015%2F11%2F27%2Fopinion%2Fturn-the-volume-down-on-drug-ads.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Suttle, Rick (2016). \"Example of organizational ethics\". <i>smallbusiness.chron.com</i>. Houston Chronicle.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=smallbusiness.chron.com&amp;rft.atitle=Example+of+organizational+ethics&amp;rft.date=2016&amp;rft.aulast=Suttle&amp;rft.aufirst=Rick&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span> <span style=\"display:none;font-size:100%\" class=\"error citation-comment\">Missing or empty <code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;url=</code> (<a href=\"/wiki/Help:CS1_errors#cite_web_url\" title=\"Help:CS1 errors\">help</a>); </span><span style=\"display:none;font-size:100%\" class=\"error citation-comment\"><code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;access-date=</code> requires <code style=\"color:inherit; border:inherit; padding:inherit;\">&#124;url=</code> (<a href=\"/wiki/Help:CS1_errors#accessdate_missing_url\" title=\"Help:CS1 errors\">help</a>)</span></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Collier, R (2009). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2630351\">\"Drug development cost estimates hard to swallow\"</a>. <i>CMAJ</i>. <b>180</b>: 279\u201380. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1503/cmaj.082040\">10.1503/cmaj.082040</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC2630351\">2630351</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/19188620\">19188620</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CMAJ&amp;rft.atitle=Drug+development+cost+estimates+hard+to+swallow&amp;rft.volume=180&amp;rft.pages=279-80&amp;rft.date=2009&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2630351&amp;rft_id=info%3Apmid%2F19188620&amp;rft_id=info%3Adoi%2F10.1503%2Fcmaj.082040&amp;rft.aulast=Collier&amp;rft.aufirst=R&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2630351&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-Baltimore-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Baltimore_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Baltimore_4-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Baltimore_4-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Baltimore_4-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-Baltimore_4-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation news\">Anderson, Tania (27 June 2003). \"Just what the doctor ordered\". <i>Baltimore Business Journal</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Baltimore+Business+Journal&amp;rft.atitle=Just+what+the+doctor+ordered&amp;rft.date=2003-06-27&amp;rft.au=Anderson%2C+Tania&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-FBIFraudTypes-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-FBIFraudTypes_5-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fbi.gov/stats-services/publications/fcs_report2006/financial-crimes-report-to-the-public-fiscal-year-2006#Health\">\"Financial Crimes to the Public Report 2006\"</a>. FBI. 2006.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Financial+Crimes+to+the+Public+Report+2006&amp;rft.pub=FBI&amp;rft.date=2006&amp;rft_id=https%3A%2F%2Fwww.fbi.gov%2Fstats-services%2Fpublications%2Ffcs_report2006%2Ffinancial-crimes-report-to-the-public-fiscal-year-2006%23Health&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-FBIHealthCareGeneral-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-FBIHealthCareGeneral_6-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.fbi.gov/about-us/investigate/white_collar/health-care-fraud\">\"FBI-Health Care Fraud\"</a>. FBI.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FBI-Health+Care+Fraud&amp;rft.pub=FBI&amp;rft_id=https%3A%2F%2Fwww.fbi.gov%2Fabout-us%2Finvestigate%2Fwhite_collar%2Fhealth-care-fraud&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-DOJHealthCareFraudReport-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-DOJHealthCareFraudReport_7-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.justice.gov/usao/tne/health_care.html\">\"Department of Justice\"</a>. Department of Justice.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Department+of+Justice&amp;rft.pub=Department+of+Justice&amp;rft_id=http%3A%2F%2Fwww.justice.gov%2Fusao%2Ftne%2Fhealth_care.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-bied2010-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-bied2010_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Duff Wilson (October 2, 2010). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2010/10/03/business/03psych.html?_r=3&amp;hp=&amp;pagewanted=all\">\"Side Effects May Include Lawsuits\"</a>. <i>New York Times</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=Side+Effects+May+Include+Lawsuits&amp;rft.date=2010-10-02&amp;rft.au=Duff+Wilson&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2010%2F10%2F03%2Fbusiness%2F03psych.html%3F_r%3D3%26hp%3D%26pagewanted%3Dall&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-9\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.bbc.co.uk/news/world-us-canada-18673220\">\"GlaxoSmithKline\"</a>. <i>BBC News</i>. 4 July 2012.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BBC+News&amp;rft.atitle=GlaxoSmithKline&amp;rft.date=2012-07-04&amp;rft_id=https%3A%2F%2Fwww.bbc.co.uk%2Fnews%2Fworld-us-canada-18673220&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.bloomberg.com/news/2012-07-02/glaxosmithkline-agrees-to-pay-3-billion-in-u-s-drug-settlement.html\">\"GlaxoSmithKline Agrees to Pay $3 Billion in U.S. Drug Settlement\"</a>. <i>Bloomberg</i>. 2 July 2012.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bloomberg&amp;rft.atitle=GlaxoSmithKline+Agrees+to+Pay+%243+Billion+in+U.S.+Drug+Settlement&amp;rft.date=2012-07-02&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2F2012-07-02%2Fglaxosmithkline-agrees-to-pay-3-billion-in-u-s-drug-settlement.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-11\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-11\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Fred Mogul (2 July 2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://web.archive.org/web/20130419053720/http://www.wnyc.org/articles/wnyc-news/2012/jul/02/drug-giant-pays-record-setting-fine/\">\"NY to Get Millions in GlaxoSmithKlein Settlement\"</a>. <a href=\"/wiki/WNYC\" title=\"WNYC\">WNYC</a>. Archived from <a rel=\"nofollow\" class=\"external text\" href=\"http://www.wnyc.org/articles/wnyc-news/2012/jul/02/drug-giant-pays-record-setting-fine/\">the original</a> on 19 April 2013<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 July</span> 2012</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=NY+to+Get+Millions+in+GlaxoSmithKlein+Settlement&amp;rft.pub=WNYC&amp;rft.date=2012-07-02&amp;rft.au=Fred+Mogul&amp;rft_id=http%3A%2F%2Fwww.wnyc.org%2Farticles%2Fwnyc-news%2F2012%2Fjul%2F02%2Fdrug-giant-pays-record-setting-fine%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.bbc.co.uk/news/world-us-canada-18673220\">\"BBC News -GlaxoSmithKline to pay $3bn in US drug fraud scandal\"</a>. <i><a href=\"/wiki/BBC_Online\" title=\"BBC Online\">BBC Online</a></i>. 2012-07-02<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2 July</span> 2012</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BBC+Online&amp;rft.atitle=BBC+News+-GlaxoSmithKline+to+pay+%243bn+in+US+drug+fraud+scandal&amp;rft.date=2012-07-02&amp;rft_id=https%3A%2F%2Fwww.bbc.co.uk%2Fnews%2Fworld-us-canada-18673220&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Thomas, Katie; Schmidt, Michael S. (July 2, 2012). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html\">\"Glaxo Agrees to Pay $3 Billion in Fraud Settlement\"</a>. <i>The New York Times</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">July 3,</span> 2012</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Glaxo+Agrees+to+Pay+%243+Billion+in+Fraud+Settlement&amp;rft.date=2012-07-02&amp;rft.au=Thomas%2C+Katie&amp;rft.au=Schmidt%2C+Michael+S.&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2012%2F07%2F03%2Fbusiness%2Fglaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\">Sammy Almashat, M.D., M.P.H.,  Charles Preston, M.D., M.P.H., Timothy Waterman, B.S., Sidney Wolfe, M.D., Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry:  1991 \u2013 2010, Public Citizen\u2019s Health Research Group, December 16, 2010</span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Thomas, Katie; Schmidt, Michael S. (2012-07-02). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html?pagewanted=all\">\"GlaxoSmithKline Agrees to Pay $3 Billion in Fraud Settlement\"</a>. <i>The New York Times</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=GlaxoSmithKline+Agrees+to+Pay+%243+Billion+in+Fraud+Settlement&amp;rft.date=2012-07-02&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft.au=Schmidt%2C+Michael+S.&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2012%2F07%2F03%2Fbusiness%2Fglaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html%3Fpagewanted%3Dall&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.justice.gov/opa/pr/2012/July/12-civ-842.html\">\"USDOJ: GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data\"</a>. Justice.gov. 2012-07-02<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2013-09-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=USDOJ%3A+GlaxoSmithKline+to+Plead+Guilty+and+Pay+%243+Billion+to+Resolve+Fraud+Allegations+and+Failure+to+Report+Safety+Data&amp;rft.pub=Justice.gov&amp;rft.date=2012-07-02&amp;rft_id=http%3A%2F%2Fwww.justice.gov%2Fopa%2Fpr%2F2012%2FJuly%2F12-civ-842.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-17\">^</a></b></span> <span class=\"reference-text\"><a rel=\"nofollow\" class=\"external free\" href=\"http://www.justice.gov/usao/ma/news/Pfizer/Pfizer%20-%20PR%20(Final).pdf\">http://www.justice.gov/usao/ma/news/Pfizer/Pfizer%20-%20PR%20(Final).pdf</a></span>\n</li>\n<li id=\"cite_note-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-18\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.justice.gov/opa/pr/2012/May/12-civ-585.html\">\"USDOJ: Abbott Labs to Pay $1.5 Billion to Resolve Criminal &amp; Civil Investigations of Off-label Promotion of Depakote\"</a>. Justice.gov. 2012-05-07<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2013-09-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=USDOJ%3A+Abbott+Labs+to+Pay+%241.5+Billion+to+Resolve+Criminal+%26+Civil+Investigations+of+Off-label+Promotion+of+Depakote&amp;rft.pub=Justice.gov&amp;rft.date=2012-05-07&amp;rft_id=http%3A%2F%2Fwww.justice.gov%2Fopa%2Fpr%2F2012%2FMay%2F12-civ-585.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.justice.gov/opa/pr/2009/January/09-civ-038.html\">\"#09-038: Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa (2009-01-15)\"</a>. Justice.gov<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2013-09-06</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=%2309-038%3A+Eli+Lilly+and+Company+Agrees+to+Pay+%241.415+Billion+to+Resolve+Allegations+of+Off-label+Promotion+of+Zyprexa+%282009-01-15%29&amp;rft.pub=Justice.gov&amp;rft_id=http%3A%2F%2Fwww.justice.gov%2Fopa%2Fpr%2F2009%2FJanuary%2F09-civ-038.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"Further_reading\">Further reading</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Ethics_in_pharmaceutical_sales&amp;action=edit&amp;section=12\" title=\"Edit section: Further reading\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"div-col columns column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em;\">\n<p><cite class=\"citation book\">Grace, Damian; Stephen Cohen (2005). <i>Business Ethics</i>. Victoria: <a href=\"/wiki/Oxford_University_Press\" title=\"Oxford University Press\">Oxford University Press</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Business+Ethics&amp;rft.place=Victoria&amp;rft.pub=Oxford+University+Press&amp;rft.date=2005&amp;rft.aulast=Grace&amp;rft.aufirst=Damian&amp;rft.au=Stephen+Cohen&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation journal\">\"Sales Force Effectiveness\". Datamonitor. November 2006.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Sales+Force+Effectiveness&amp;rft.date=2006-11&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation journal\">\"The Pharmaceutical Industry: Key events and trends\". Datamonitor. March 2006.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+Pharmaceutical+Industry%3A+Key+events+and+trends&amp;rft.date=2006-03&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.efpia.org/Content/Default.asp?PageID=152\">\"European Federation of Pharmaceutical Industries and Association, Corporate and Social Responsibility\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2007-10-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=European+Federation+of+Pharmaceutical+Industries+and+Association%2C+Corporate+and+Social+Responsibility&amp;rft_id=http%3A%2F%2Fwww.efpia.org%2FContent%2FDefault.asp%3FPageID%3D152&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.efpia.org/Content/Default.asp?PageID=150\">\"European Federation of Pharmaceutical Industries and Association, Promotion of Medicine\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2007-10-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=European+Federation+of+Pharmaceutical+Industries+and+Association%2C+Promotion+of+Medicine&amp;rft_id=http%3A%2F%2Fwww.efpia.org%2FContent%2FDefault.asp%3FPageID%3D150&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.efpia.org/content/default.asp?PageID=199\">\"European Federation of Pharmaceutical Industries and Associations, The Pharma Industry of figures 2006\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2007-10-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=European+Federation+of+Pharmaceutical+Industries+and+Associations%2C+The+Pharma+Industry+of+figures+2006&amp;rft_id=http%3A%2F%2Fwww.efpia.org%2Fcontent%2Fdefault.asp%3FPageID%3D199&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation news\">\"Sales Force Survey\". European Pharmaceutical Executive. January\u2013February 2004.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Sales+Force+Survey&amp;rft.date=2004-01%2F2004-02&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation journal\">Mackintosh, Alasdair (2004). \"Marketing Strategy, Innovation in the pharmaceutical marketing strategy: How to overcome the 30-second detailing dilemma\". <i>International Journal of Medical Marketing</i>. <b>4</b> (1): 15\u201317. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1057/palgrave.jmm.5040138\">10.1057/palgrave.jmm.5040138</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Medical+Marketing&amp;rft.atitle=Marketing+Strategy%2C+Innovation+in+the+pharmaceutical+marketing+strategy%3A+How+to+overcome+the+30-second+detailing+dilemma&amp;rft.volume=4&amp;rft.issue=1&amp;rft.pages=15-17&amp;rft.date=2004&amp;rft_id=info%3Adoi%2F10.1057%2Fpalgrave.jmm.5040138&amp;rft.aulast=Mackintosh&amp;rft.aufirst=Alasdair&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.nofreelunch.org/changingbehavior.htm\">\"No Free Lunch\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2007-10-14</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=No+Free+Lunch&amp;rft_id=http%3A%2F%2Fwww.nofreelunch.org%2Fchangingbehavior.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation news\">\"Drug Firms a Danger to Health\". The Guardian. 2004-06-26.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Drug+Firms+a+Danger+to+Health&amp;rft.date=2004-06-26&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><cite class=\"citation journal\">Wright, Robert F.; William J. Lundstrom. \"Physicians' perception of pharmaceutical sales representative: A model for analysing the customer relationship\". <i>International Journal of Medical Marketing</i>. <b>4</b> (1): 20\u201338. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1057/palgrave.jmm.5040140\">10.1057/palgrave.jmm.5040140</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Journal+of+Medical+Marketing&amp;rft.atitle=Physicians%E2%80%99+perception+of+pharmaceutical+sales+representative%3A+A+model+for+analysing+the+customer+relationship&amp;rft.volume=4&amp;rft.issue=1&amp;rft.pages=20-38&amp;rft_id=info%3Adoi%2F10.1057%2Fpalgrave.jmm.5040140&amp;rft.aulast=Wright&amp;rft.aufirst=Robert+F.&amp;rft.au=William+J.+Lundstrom&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AEthics+in+pharmaceutical+sales\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span>\n</p><p><i><a href=\"/wiki/Big_Pharma_(book)\" title=\"Big Pharma (book)\">Big Pharma: How the World's Biggest Drug Companies Control Illness</a></i> (2006) by Jacky Law\n</p><p><i><a href=\"/wiki/Side_Effects_(Bass_book)\" title=\"Side Effects (Bass book)\">Side Effects</a></i> (2008) by <a href=\"/wiki/Alison_Bass\" title=\"Alison Bass\">Alison Bass</a>\n</p><p><i><a href=\"/wiki/Anatomy_of_an_Epidemic\" title=\"Anatomy of an Epidemic\">Anatomy of an Epidemic</a></i> (2010) by <a href=\"/wiki/Robert_Whitaker_(author)\" title=\"Robert Whitaker (author)\">Robert Whitaker</a>\n</p><p><i><a href=\"/wiki/Bad_Pharma\" title=\"Bad Pharma\">Bad Pharma: How drug companies mislead doctors and harm patients</a></i> (2012) by <a href=\"/wiki/Ben_Goldacre\" title=\"Ben Goldacre\">Ben Goldacre</a>\n</p>\n</div>\n\n<!-- \nNewPP limit report\nParsed by mw1288\nCached time: 20180905190509\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.268 seconds\nReal time usage: 0.298 seconds\nPreprocessor visited node count: 1069/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 41584/2097152 bytes\nTemplate argument size: 221/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 21024/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.148/10.000 seconds\nLua memory usage: 3.56 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  247.247      1 -total\n 50.54%  124.964      1 Template:Reflist\n 27.41%   67.767     10 Template:Cite_news\n 21.13%   52.233     12 Template:Cite_web\n 14.47%   35.771      5 Template:Cite_journal\n 10.02%   24.773      3 Template:Main_article\n  3.58%    8.853      1 Template:Cite_book\n  2.15%    5.325      1 Template:See_also\n  1.52%    3.753      1 Template:Div_col\n  1.29%    3.199      2 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:13789612-0!canonical and timestamp 20180905190509 and revision id 858207187\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","hidden":"","*":"Pages_using_web_citations_with_no_URL"},{"sortkey":"","hidden":"","*":"Pages_using_citations_with_accessdate_and_no_URL"},{"sortkey":"","*":"Medical_ethics"},{"sortkey":"","*":"Business_ethics"}],"links":[{"ns":0,"exists":"","*":"Abbott Laboratories"},{"ns":0,"exists":"","*":"Advair"},{"ns":0,"exists":"","*":"Alison Bass"},{"ns":0,"exists":"","*":"Anatomy of an Epidemic"},{"ns":0,"exists":"","*":"AstraZeneca"},{"ns":0,"exists":"","*":"BBC Online"},{"ns":0,"exists":"","*":"Bad Pharma"},{"ns":0,"exists":"","*":"Ben Goldacre"},{"ns":0,"exists":"","*":"Bextra"},{"ns":0,"exists":"","*":"Big Pharma (book)"},{"ns":0,"exists":"","*":"Bribing"},{"ns":0,"exists":"","*":"Bristol-Myers Squibb"},{"ns":0,"exists":"","*":"Bupropion"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Drug development"},{"ns":0,"exists":"","*":"Drug discovery"},{"ns":0,"exists":"","*":"Eli Lilly"},{"ns":0,"exists":"","*":"Eli Lilly and Company"},{"ns":0,"exists":"","*":"European Federation of Pharmaceutical Industries and Associations"},{"ns":0,"exists":"","*":"False Claims Act"},{"ns":0,"exists":"","*":"Families USA"},{"ns":0,"exists":"","*":"Federal Bureau of Investigation"},{"ns":0,"exists":"","*":"Federal Food, Drug, and Cosmetic Act"},{"ns":0,"exists":"","*":"Flovent"},{"ns":0,"exists":"","*":"Geodon"},{"ns":0,"exists":"","*":"GlaxoSmithKline"},{"ns":0,"exists":"","*":"Health care fraud"},{"ns":0,"exists":"","*":"Health care system"},{"ns":0,"exists":"","*":"Imitrex"},{"ns":0,"exists":"","*":"Inverse benefit law"},{"ns":0,"exists":"","*":"Johnson & Johnson"},{"ns":0,"exists":"","*":"Kickback (bribery)"},{"ns":0,"exists":"","*":"Kickbacks"},{"ns":0,"exists":"","*":"Lamictal"},{"ns":0,"exists":"","*":"Linezolid"},{"ns":0,"exists":"","*":"List of largest pharmaceutical settlements in the United States"},{"ns":0,"exists":"","*":"List of off-label promotion pharmaceutical settlements"},{"ns":0,"exists":"","*":"Lotronex"},{"ns":0,"exists":"","*":"Medicare (United States)"},{"ns":0,"exists":"","*":"Medicare fraud"},{"ns":0,"exists":"","*":"Merck & Co."},{"ns":0,"exists":"","*":"New York Times"},{"ns":0,"exists":"","*":"No Free Lunch (organization)"},{"ns":0,"exists":"","*":"Off-label use"},{"ns":0,"exists":"","*":"Olanzapine"},{"ns":0,"exists":"","*":"Organizational ethics"},{"ns":0,"exists":"","*":"Oxford University Press"},{"ns":0,"exists":"","*":"Paroxetine"},{"ns":0,"exists":"","*":"Paxil"},{"ns":0,"exists":"","*":"Pfizer"},{"ns":0,"exists":"","*":"Pharmaceutical Research and Manufacturers of America"},{"ns":0,"exists":"","*":"Pharmaceutical fraud"},{"ns":0,"exists":"","*":"Pharmaceutical industry"},{"ns":0,"exists":"","*":"Pharmaceutical marketing"},{"ns":0,"exists":"","*":"Pharmaceutical sales representative"},{"ns":0,"exists":"","*":"Pregabalin"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"Public Citizen"},{"ns":0,"exists":"","*":"Qui tam"},{"ns":0,"exists":"","*":"Relator (law)"},{"ns":0,"exists":"","*":"Robert Whitaker (author)"},{"ns":0,"exists":"","*":"Rosiglitazone"},{"ns":0,"exists":"","*":"Side Effects (Bass book)"},{"ns":0,"exists":"","*":"United States Department of Health and Human Services"},{"ns":0,"exists":"","*":"Valdecoxib"},{"ns":0,"exists":"","*":"Valproic acid"},{"ns":0,"exists":"","*":"Valtrex"},{"ns":0,"exists":"","*":"WNYC"},{"ns":0,"exists":"","*":"Wellbutrin"},{"ns":0,"exists":"","*":"Whistleblower"},{"ns":0,"exists":"","*":"Ziprasidone"},{"ns":0,"exists":"","*":"Zofran"},{"ns":0,"exists":"","*":"Zyprexa"},{"ns":12,"exists":"","*":"Help:CS1 errors"}],"templates":[{"ns":10,"exists":"","*":"Template:Main article"},{"ns":10,"exists":"","*":"Template:Main"},{"ns":10,"exists":"","*":"Template:See also"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Div col"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:Div col end"},{"ns":828,"exists":"","*":"Module:Main"},{"ns":828,"exists":"","*":"Module:Hatnote"},{"ns":828,"exists":"","*":"Module:Hatnote list"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Labelled list hatnote"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Lock-green.svg"],"externallinks":["https://www.nytimes.com/2015/11/27/opinion/turn-the-volume-down-on-drug-ads.html","//www.ncbi.nlm.nih.gov/pmc/articles/PMC2630351","//doi.org/10.1503/cmaj.082040","//www.ncbi.nlm.nih.gov/pubmed/19188620","https://www.fbi.gov/stats-services/publications/fcs_report2006/financial-crimes-report-to-the-public-fiscal-year-2006#Health","https://www.fbi.gov/about-us/investigate/white_collar/health-care-fraud","http://www.justice.gov/usao/tne/health_care.html","https://www.nytimes.com/2010/10/03/business/03psych.html?_r=3&hp=&pagewanted=all","https://www.bbc.co.uk/news/world-us-canada-18673220","https://www.bloomberg.com/news/2012-07-02/glaxosmithkline-agrees-to-pay-3-billion-in-u-s-drug-settlement.html","https://web.archive.org/web/20130419053720/http://www.wnyc.org/articles/wnyc-news/2012/jul/02/drug-giant-pays-record-setting-fine/","http://www.wnyc.org/articles/wnyc-news/2012/jul/02/drug-giant-pays-record-setting-fine/","https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html","https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html?pagewanted=all","http://www.justice.gov/opa/pr/2012/July/12-civ-842.html","http://www.justice.gov/opa/pr/2012/May/12-civ-585.html","http://www.justice.gov/opa/pr/2009/January/09-civ-038.html","http://www.justice.gov/usao/ma/news/Pfizer/Pfizer%20-%20PR%20(Final).pdf","http://www.efpia.org/Content/Default.asp?PageID=152","http://www.efpia.org/Content/Default.asp?PageID=150","http://www.efpia.org/content/default.asp?PageID=199","//doi.org/10.1057/palgrave.jmm.5040138","http://www.nofreelunch.org/changingbehavior.htm","//doi.org/10.1057/palgrave.jmm.5040140"],"sections":[{"toclevel":1,"level":"2","line":"Industry","number":"1","index":"1","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":920,"anchor":"Industry"},{"toclevel":1,"level":"2","line":"Sales practices","number":"2","index":"2","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":2043,"anchor":"Sales_practices"},{"toclevel":1,"level":"2","line":"Regulations and guidelines","number":"3","index":"3","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":2596,"anchor":"Regulations_and_guidelines"},{"toclevel":2,"level":"3","line":"European Federation of Pharmaceutical Industries and Associations","number":"3.1","index":"4","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":2630,"anchor":"European_Federation_of_Pharmaceutical_Industries_and_Associations"},{"toclevel":2,"level":"3","line":"Pharmaceutical Research and Manufacturers of America","number":"3.2","index":"5","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":3559,"anchor":"Pharmaceutical_Research_and_Manufacturers_of_America"},{"toclevel":2,"level":"3","line":"U.S. Department of Health and Human Services","number":"3.3","index":"6","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":5647,"anchor":"U.S._Department_of_Health_and_Human_Services"},{"toclevel":1,"level":"2","line":"Health care fraud","number":"4","index":"7","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":6118,"anchor":"Health_care_fraud"},{"toclevel":1,"level":"2","line":"Advocacy groups","number":"5","index":"8","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":13904,"anchor":"Advocacy_groups"},{"toclevel":2,"level":"3","line":"No Free Lunch","number":"5.1","index":"9","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":13925,"anchor":"No_Free_Lunch"},{"toclevel":1,"level":"2","line":"See also","number":"6","index":"10","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":14307,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"7","index":"11","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":14380,"anchor":"References"},{"toclevel":1,"level":"2","line":"Further reading","number":"8","index":"12","fromtitle":"Ethics_in_pharmaceutical_sales","byteoffset":14412,"anchor":"Further_reading"}],"parsewarnings":[],"displaytitle":"Ethics in pharmaceutical sales","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q17157034"}]}}